Henry Schein, Inc. (NASDAQ:HSIC) Shares Purchased by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 5.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 122,721 shares of the company’s stock after purchasing an additional 6,826 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned approximately 0.10% of Henry Schein worth $8,946,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Swedbank AB acquired a new stake in Henry Schein in the first quarter valued at $215,998,000. ING Groep NV acquired a new stake in shares of Henry Schein in the third quarter valued at about $63,226,000. Thompson Siegel & Walmsley LLC purchased a new stake in Henry Schein during the second quarter worth about $46,683,000. SG Americas Securities LLC grew its position in Henry Schein by 1,622.3% during the third quarter. SG Americas Securities LLC now owns 458,828 shares of the company’s stock worth $33,449,000 after buying an additional 432,187 shares during the period. Finally, Nuance Investments LLC grew its holdings in shares of Henry Schein by 22.3% in the 3rd quarter. Nuance Investments LLC now owns 2,278,081 shares of the company’s stock worth $166,072,000 after acquiring an additional 414,748 shares during the period. 96.62% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Henry Schein news, SVP Lorelei Mcglynn sold 21,035 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the sale, the senior vice president now directly owns 71,833 shares in the company, valued at $4,978,026.90. This represents a 22.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Michael S. Ettinger sold 12,240 shares of Henry Schein stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $75.00, for a total value of $918,000.00. Following the completion of the transaction, the chief operating officer now directly owns 87,706 shares in the company, valued at $6,577,950. This represents a 12.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by insiders.

Henry Schein Price Performance

HSIC stock opened at $75.08 on Monday. The stock has a market capitalization of $9.36 billion, a price-to-earnings ratio of 30.90, a price-to-earnings-growth ratio of 2.12 and a beta of 0.87. The stock’s fifty day simple moving average is $70.89 and its 200-day simple moving average is $69.73. Henry Schein, Inc. has a 52-week low of $63.67 and a 52-week high of $82.63. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.17 by $0.05. The company had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm’s revenue was up .4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.32 EPS. Equities research analysts expect that Henry Schein, Inc. will post 4.78 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have commented on HSIC. JPMorgan Chase & Co. decreased their target price on Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Barrington Research reiterated an “outperform” rating and issued a $82.00 price objective on shares of Henry Schein in a research report on Wednesday, November 6th. StockNews.com upgraded shares of Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Evercore ISI upped their price target on shares of Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a report on Tuesday, October 8th. Finally, Robert W. Baird dropped their price objective on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Six investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $78.89.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.